昌红科技(300151) - 2024年8月12日投资者关系活动记录表

Group 1: Financial Performance - The company achieved a total revenue of 483 million yuan in the first half of 2024, with a net profit attributable to shareholders of 44 million yuan, reflecting a year-on-year decrease of 5.94% and a growth of 2.42% respectively [2] - The net profit margin after deducting non-recurring gains and losses was 0.54% [2] - The medical device sector experienced a growth of 18.12% in revenue during the same period [2] Group 2: Product Development and Market Validation - Multiple products have entered the "small batch and verification" stage at major domestic wafer factories, with ongoing efforts to expedite formal production line validation [3] - The company has established a strategic cooperation framework with Fresenius, which began in June 2024, focusing on close communication regarding specific projects [3] - The company specializes in high-end medical plastic products, relying on precision molds and automated production technology, with a dedicated team for mold design and automated production line development [3]